debrisoquin has been researched along with Neoplasms in 18 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The variation in plasma morphine concentrations was higher than that of oxycodone, consistent with the lower bioavailability of morphine." | 6.69 | Morphine or oxycodone in cancer pain? ( Heiskanen, TE; Kalso, EA; Ruismäki, PM; Seppälä, TA, 2000) |
| " Three examples of pharmacogenetic risk factors are discussed: the first two are p450 enzymes whose activity has been associated with susceptibility to lung cancer (debrisoquine hydroxylase, aryl hydrocarbon hydroxylase), and the last, N-acetyltransferase, a non-p450 enzyme, has been associated with bladder cancer susceptibility." | 3.68 | Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens. ( Caporaso, N, 1991) |
| " The variation in plasma morphine concentrations was higher than that of oxycodone, consistent with the lower bioavailability of morphine." | 2.69 | Morphine or oxycodone in cancer pain? ( Heiskanen, TE; Kalso, EA; Ruismäki, PM; Seppälä, TA, 2000) |
| "The application of biomarkers to cancer epidemiology should enhance the validity of exposure and outcome measurement, and strengthen the statistical association between exposure and diseases, thus reducing the possibility of random and systematic error." | 1.29 | Sources of bias, effect of confounding in the application of biomarkers to epidemiological studies. ( Boffetta, P, 1995) |
| "Accordingly, two groups of cancer patients were investigated with debrisoquine, namely Nigerians with hepatocellular and related tumours and white smokers with bronchial carcinoma in the United Kingdom." | 1.26 | Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis. ( Idle, JR; Ritchie, JC, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (38.89) | 18.7374 |
| 1990's | 10 (55.56) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanke, JZ | 1 |
| Nemoto, N | 1 |
| Ritchie, JC | 1 |
| Idle, JR | 1 |
| Vineis, P | 1 |
| Boffetta, P | 1 |
| Anthony, LB | 1 |
| Boeve, TJ | 1 |
| Hande, KR | 1 |
| Sinués, B | 1 |
| Rueda, P | 1 |
| Benítez, J | 1 |
| Saenz, MA | 1 |
| Bernal, ML | 1 |
| Lanuza, J | 1 |
| Alda, O | 1 |
| Tres, A | 1 |
| Bartolome, M | 1 |
| Nebert, DW | 5 |
| Heiskanen, TE | 1 |
| Ruismäki, PM | 1 |
| Seppälä, TA | 1 |
| Kalso, EA | 1 |
| Caporaso, N | 1 |
| Sugimura, H | 1 |
| Caporaso, NE | 1 |
| Shaw, GL | 1 |
| Modali, RV | 1 |
| Gonzalez, FJ | 3 |
| Hoover, RN | 1 |
| Resau, JH | 1 |
| Trump, BF | 1 |
| Weston, A | 1 |
| Harris, CC | 1 |
| Philip, PA | 1 |
| Lewis, LD | 1 |
| James, CA | 1 |
| Rogers, HJ | 1 |
| Jaiswal, AK | 1 |
| Meyer, UA | 1 |
| Barbeau, A | 1 |
| Roy, M | 1 |
| Cloutier, T | 1 |
5 reviews available for debrisoquin and Neoplasms
| Article | Year |
|---|---|
[Individual difference in drug metabolism--pharmacogenetical approach].
Topics: Absorption; Animals; Debrisoquin; Female; Genetics; Guinea Pigs; Humans; Isoquinolines; Kinetics; Mi | 1982 |
Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?
Topics: Acetylation; Animals; Arylamine N-Acetyltransferase; Bioethics; Cytochrome P-450 CYP2D6; Debrisoquin | 1997 |
Role of genetics and drug metabolism in human cancer risk.
Topics: Acetylation; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Debrisoquin; Gene Expres | 1991 |
Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility.
Topics: Animals; Biotransformation; Carcinogens; Cytochrome P-450 Enzyme System; Debrisoquin; Genetic Predis | 1990 |
Genes encoding drug-metabolizing enzymes: possible role in human disease.
Topics: Acetylation; Acetyltransferases; Chromosome Mapping; Cytochrome P-450 Enzyme System; Debrisoquin; Ge | 1988 |
1 trial available for debrisoquin and Neoplasms
| Article | Year |
|---|---|
Morphine or oxycodone in cancer pain?
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Cross-Over Studies; Cytochrome P-450 CYP2D6; | 2000 |
12 other studies available for debrisoquin and Neoplasms
| Article | Year |
|---|---|
Genetic susceptibility to toxic substances and its relationship to carcinogenesis.
Topics: Acetylation; alpha 1-Antitrypsin; Aryl Hydrocarbon Hydroxylases; Carcinogens; Debrisoquin; Disease S | 1984 |
Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
Topics: Animals; Biotransformation; Carcinoma, Bronchogenic; Debrisoquin; Humans; Isoquinolines; Lung Neopla | 1982 |
Use of biomarkers in epidemiology. The example of metabolic susceptibility to cancer.
Topics: Biomarkers; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Disease Susceptibi | 1995 |
Sources of bias, effect of confounding in the application of biomarkers to epidemiological studies.
Topics: Bias; Biomarkers; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Diagnostic E | 1995 |
Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
Topics: Aged; Chromatography, Gas; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome | 1995 |
Thioether excretion, urinary mutagenicity, and metabolic phenotype in smokers.
Topics: Acetylation; Adult; Biomarkers; Creatinine; Debrisoquin; Female; Genetic Predisposition to Disease; | 1994 |
Identification of genetic differences in drug metabolism: prediction of individual risk of toxicity or cancer.
Topics: Alleles; Debrisoquin; Forecasting; Genes; Genetic Predisposition to Disease; Humans; Metabolism; Mut | 1991 |
Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Topics: Biotransformation; Carcinogens, Environmental; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytoch | 1991 |
Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cytochrome P-450 CYP2D6; Cytochrome | 1990 |
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Topics: Adult; Aged; Alkylation; Debrisoquin; Female; Humans; Ifosfamide; Isoquinolines; Male; Middle Aged; | 1988 |
Human P-450 genes: evolution, regulation and possible role in carcinogenesis.
Topics: Aryl Hydrocarbon Hydroxylases; Biological Evolution; Cloning, Molecular; Cytochrome P-450 Enzyme Sys | 1987 |
Smoking, cancer, and Parkinson's disease.
Topics: Aged; Debrisoquin; Female; Humans; Hydroxylation; Isoquinolines; Kinetics; Male; Middle Aged; Neopla | 1986 |